English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

After encouraging preclinical and human dosimetry results for the novel estrogen receptor (ER) PET radiotracer 4-fluoro-11β-methoxy-16α- 18 F-fluoroestradiol ( 18 F-4FMFES), a phase II clinical trial was initiated to compare the PET imaging diagnostic potential of 18 F-4FMFES with that of 16α- 18 F-fluoroestradiol ( 18 F-FES) in ER-positive (ER+) breast cancer patients. Methods: Patients diagnosed with ER+ breast cancer ( n = 31) were recruited for this study, including 6 who underwent mastectomy or axillary node dissection. For each patient, 18 F-FES and 18 F-4FMFES PET/CT scans were done sequentially (within a week) and in random order. One hour after injection of either radiotracer, a head-to-thigh static scan with a 2-min acquisition per bed position was obtained. Blood samples were taken at different times after injection to assess each tracer metabolism by reverse-phase thin-layer chromatography. The SUV mean of nonspecific tissues and the SUV max of the tumor were evaluated for each detected lesion, and tumor-to-nonspecific organ ratios were calculated. Results: Blood metabolite analysis 60 min after injection of the tracer showed a 2.5-fold increase in metabolic stability of 18 F-4FMFES over 18 F-FES. Although for most foci 18 F-4FMFES PET had an SUV max similar to that of 18 F-FES PET, tumor contrast improved substantially in all cases. Lower uptake was consistently observed in nonspecific tissues for 18 F-4FMFES, notably a 4-fold decrease in blood-pool activity as compared with 18 F-FES. Consequently, image quality was considerably improved using 18 F-4FMFES, with lower overall background activity. As a result, 18 F-4FMFES successfully identified 9 more lesions than 18 F-FES. Conclusion: This phase II study with ER+ breast cancer patients showed that 18 F-4FMFES PET achieves a lower nonspecific signal and better tumor contrast than 18 F-FES PET, resulting in improved diagnostic confidence and lower false-negative diagnoses.

the journal of nuclear medicine

Improved Estrogen Receptor Assessment by PET Using the Novel Radiotracer <sup>18</sup>F-4FMFES in Estrogen Receptor–Positive Breast Cancer Patients: An Ongoing Phase II Clinical Trial

Improved Estrogen Receptor Assessment by PET Using the Novel Radiotracer 18F-4FMFES in Estrogen Receptor–Positive Breast Cancer Patients: An Ongoing Phase II Clinical Trial

Improved Estrogen Receptor Assessment by PET Using the Novel Radiotracer ¹⁸F-4FMFES in Estrogen Receptor–Positive Breast Cancer Patients: An Ongoing Phase II Clinical Trial